UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 50,822 Shares of Heartflow, Inc. $HTFL

Key Points

• UBS Asset Management increased its Heartflow position by 3.6% in the second quarter, purchasing 50,822 shares and bringing its holdings to 1.47 million shares, or 1.7% of the company.
• Heartflow reported quarterly revenue of $64.08 million, up 47.7% year over year, and a loss of $0.07 per share that beat analyst expectations. Despite growth, the company posted a negative net margin of 55.82%.
• Analysts remain broadly optimistic, with a consensus “Moderate Buy” rating and an average price target of $43.43; however, insiders have sold 191,271 shares worth approximately $7.1 million over the past 90 days.

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Heartflow, Inc. (NASDAQ:HTFL - Free Report) by 3.6% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,465,650 shares of the company's stock after purchasing an additional 50,822 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 1.70% of Heartflow worth $43,002,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. TrueMark Investments LLC lifted its holdings in shares of Heartflow by 1.4% during the first quarter. TrueMark Investments LLC now owns 26,885 shares of the company's stock valued at $654,000 after purchasing an additional 379 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in shares of Heartflow in the fourth quarter worth approximately $27,000. Strs Ohio boosted its stake in shares of Heartflow by 35.3% during the 1st quarter. Strs Ohio now owns 4,600 shares of the company's stock worth $112,000 after acquiring an additional 1,200 shares during the last quarter. Russell Investments Group Ltd. bought a new position in Heartflow in the 4th quarter worth $45,000. Finally, Legal & General Group Plc purchased a new position in Heartflow during the third quarter valued at $59,000.

Heartflow Price Performance

Heartflow stock opened at $49.71 on Friday. Heartflow, Inc. has a 1 year low of $20.13 and a 1 year high of $51.78. The firm's 50 day moving average price is $33.50 and its 200-day moving average price is $29.79. The stock has a market cap of $4.32 billion and a P/E ratio of -27.16.

Heartflow (NASDAQ:HTFL - Get Free Report) last issued its earnings results on Thursday, August 13th. The company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.22) by $0.15. The firm had revenue of $64.08 million during the quarter. Heartflow had a negative net margin of 55.82% and a negative return on equity of 23.52%. The business's revenue for the quarter was up 47.7% compared to the same quarter last year. As a group, equities analysts expect that Heartflow, Inc. will post -0.75 EPS for the current year.

Insider Transactions at Heartflow

In related news, CEO John Farquhar sold 38,900 shares of the company's stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $35.00, for a total transaction of $1,361,500.00. Following the sale, the chief executive officer owned 457,935 shares of the company's stock, valued at $16,027,725. This represents a 7.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Campbell Rogers sold 9,219 shares of Heartflow stock in a transaction on Monday, August 17th. The stock was sold at an average price of $41.23, for a total transaction of $380,099.37. Following the completion of the transaction, the insider directly owned 86,459 shares of the company's stock, valued at $3,564,704.57. The trade was a 9.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 191,271 shares of company stock valued at $7,089,136. Company insiders own 7.70% of the company's stock.

Analyst Ratings Changes

HTFL has been the subject of a number of recent analyst reports. Stifel Nicolaus upped their price target on shares of Heartflow from $40.00 to $45.00 and gave the stock a "buy" rating in a research report on Friday, August 14th. JPMorgan Chase & Co. lifted their target price on shares of Heartflow from $35.00 to $45.00 and gave the company an "overweight" rating in a research note on Friday, August 14th. Weiss Ratings raised shares of Heartflow from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, August 7th. Piper Sandler reissued an "overweight" rating and set a $45.00 price target (up from $38.00) on shares of Heartflow in a report on Friday, August 14th. Finally, Wells Fargo & Company boosted their price objective on Heartflow from $37.00 to $39.00 and gave the company an "overweight" rating in a research report on Friday, August 14th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $43.43.

Heartflow Profile

HeartFlow, Inc NASDAQ: HTFL is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company's core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow's analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow's cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.

Want to see what other hedge funds are holding HTFL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heartflow, Inc. (NASDAQ:HTFL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.